Silverarc Capital Management LLC Acquires 771,187 Shares of Biodesix, Inc. (NASDAQ:BDSX)

Silverarc Capital Management LLC grew its stake in Biodesix, Inc. (NASDAQ:BDSX - Free Report) by 21.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,332,281 shares of the company's stock after purchasing an additional 771,187 shares during the quarter. Biodesix comprises about 1.4% of Silverarc Capital Management LLC's holdings, making the stock its 26th biggest holding. Silverarc Capital Management LLC owned about 2.98% of Biodesix worth $6,628,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently modified their holdings of the stock. Wilmington Savings Fund Society FSB purchased a new position in shares of Biodesix during the 3rd quarter worth approximately $10,849,000. Samjo Management LLC bought a new position in Biodesix in the fourth quarter worth $3,790,000. Susquehanna International Group LLP lifted its position in Biodesix by 769.8% during the fourth quarter. Susquehanna International Group LLP now owns 1,115,748 shares of the company's stock valued at $1,707,000 after buying an additional 987,475 shares during the period. AIGH Capital Management LLC boosted its holdings in shares of Biodesix by 8.8% during the 4th quarter. AIGH Capital Management LLC now owns 6,179,812 shares of the company's stock valued at $9,455,000 after buying an additional 500,000 shares in the last quarter. Finally, Perkins Capital Management Inc. grew its position in shares of Biodesix by 46.3% in the 4th quarter. Perkins Capital Management Inc. now owns 1,060,211 shares of the company's stock worth $1,622,000 after buying an additional 335,429 shares during the period. Institutional investors own 20.96% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, William Blair reaffirmed an "outperform" rating on shares of Biodesix in a research note on Tuesday, March 4th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $2.95.

Biodesix Stock Down 5.6 %

Biodesix stock traded down $0.03 during mid-day trading on Friday, reaching $0.54. The stock had a trading volume of 839,552 shares, compared to its average volume of 307,656. The company has a market capitalization of $78.93 million, a price-to-earnings ratio of -1.38 and a beta of 1.17. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.40 and a quick ratio of 3.40. Biodesix, Inc. has a one year low of $0.45 and a one year high of $2.04. The company has a 50-day moving average price of $0.70 and a two-hundred day moving average price of $1.11.

Biodesix (NASDAQ:BDSX - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. The company had revenue of $20.43 million during the quarter, compared to the consensus estimate of $19.92 million. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. On average, analysts expect that Biodesix, Inc. will post -0.35 EPS for the current fiscal year.

Insider Activity at Biodesix

In other news, CEO Scott Hutton sold 83,660 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total transaction of $76,967.20. Following the completion of the transaction, the chief executive officer now directly owns 701,947 shares of the company's stock, valued at $645,791.24. The trade was a 10.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 128,702 shares of company stock valued at $118,406 over the last ninety days. Insiders own 69.20% of the company's stock.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.